Tuomisto J, Tukiainen E, Ahlfors U G
Psychopharmacology (Berl). 1979 Oct;65(2):141-7. doi: 10.1007/BF00433040.
5-Hydroxytryptamine (5-HT) uptake was studied by using blood platelets from 13 patients with endogenous depression (Hamilton rating scale 33 +/- 7) and 13 healthy volunteers. An improved method with a short incubation time and low substrate concentration was used, and the incubation was performed in Krebs-Henseleit buffer (pH 7.4) at 37 degrees C. A clear difference in 5-HT uptake by blood platelets was noted: The Vmax of the reaction in patients was 39, and in controls 71 pmol per 2 x 10(7) platelets in 5 min. There was no significant difference in the Km. After a 4-week treatment with imipramine, a competitive inhibition of 5-HT uptake with an increased Km was seen; after a similar treatment with amoxapine there was little change in 5-HT uptake. Amoxapine was inferior to imipramine as an inhibitor of 5-HT uptake, also in vitro. There was no difference in clinical recovery in these treatment groups. These results may be of importance so as to understand the potential biological differences between depressed patients and normal persons.
采用13例内源性抑郁症患者(汉密尔顿评定量表评分为33±7)和13名健康志愿者的血小板,对5-羟色胺(5-HT)摄取进行了研究。采用了一种孵育时间短、底物浓度低的改良方法,孵育在37℃的Krebs-Henseleit缓冲液(pH 7.4)中进行。结果发现血小板对5-HT的摄取存在明显差异:患者组反应的Vmax为39,对照组为每2×10⁷个血小板在5分钟内摄取71 pmol。Km无显著差异。用丙咪嗪治疗4周后,可见对5-HT摄取的竞争性抑制,Km增加;用阿莫沙平进行类似治疗后,5-HT摄取几乎没有变化。在体外,阿莫沙平作为5-HT摄取抑制剂不如丙咪嗪。这些治疗组的临床恢复情况没有差异。这些结果对于理解抑郁症患者和正常人之间潜在的生物学差异可能具有重要意义。